Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Position Lessened by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. reduced its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 11.3% during the 4th quarter, Holdings Channel reports. The fund owned 85,086 shares of the specialty pharmaceutical company’s stock after selling 10,834 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Jazz Pharmaceuticals were worth $10,466,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Jazz Pharmaceuticals by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company’s stock valued at $825,705,000 after acquiring an additional 29,960 shares during the period. Wellington Management Group LLP increased its position in Jazz Pharmaceuticals by 7.5% in the 1st quarter. Wellington Management Group LLP now owns 2,625,134 shares of the specialty pharmaceutical company’s stock valued at $408,654,000 after acquiring an additional 184,124 shares during the period. State Street Corp increased its position in Jazz Pharmaceuticals by 1.8% in the 2nd quarter. State Street Corp now owns 2,372,395 shares of the specialty pharmaceutical company’s stock valued at $294,106,000 after acquiring an additional 42,703 shares during the period. LSV Asset Management increased its position in Jazz Pharmaceuticals by 2.4% in the 3rd quarter. LSV Asset Management now owns 2,372,177 shares of the specialty pharmaceutical company’s stock valued at $307,055,000 after acquiring an additional 55,630 shares during the period. Finally, FMR LLC increased its position in Jazz Pharmaceuticals by 8.1% in the 3rd quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company’s stock valued at $172,560,000 after acquiring an additional 100,349 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ opened at $110.58 on Friday. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37. The stock has a market capitalization of $6.97 billion, a price-to-earnings ratio of 18.07, a PEG ratio of 1.57 and a beta of 0.59. The stock’s fifty day simple moving average is $121.21 and its 200 day simple moving average is $123.21. Jazz Pharmaceuticals plc has a 52-week low of $110.42 and a 52-week high of $147.14.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. As a group, sell-side analysts forecast that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CAO Patricia Carr sold 1,936 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the transaction, the chief accounting officer now owns 8,364 shares in the company, valued at $1,000,668.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Philip L. Johnson purchased 12,000 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were acquired at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the purchase, the chief financial officer now owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Patricia Carr sold 1,936 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The disclosure for this sale can be found here. Insiders own 4.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on JAZZ. Truist Financial restated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. Piper Sandler lifted their price target on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 30th. JPMorgan Chase & Co. lifted their price target on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an “overweight” rating in a research report on Friday, March 22nd. Finally, Barclays lowered their price target on Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating on the stock in a research report on Friday, March 1st. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $195.08.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.